Literature DB >> 8203427

Three consecutive pregnancies in a patient with glycogen storage disease type IA (von Gierke's disease).

I P Ryan1, R J Havel, R K Laros.   

Abstract

Glycogen storage disease type IA is associated with metabolic abnormalities that can compromise fetal outcome. Normal outcome can be achieved by maintaining euglycemia throughout gestation. We report three consecutive pregnancies in a patient with glycogen storage disease type IA. The patient, a 35-year-old woman, has been maintained on a regimen of nightly nasogastric or cornstarch feedings for the past 12 years with improving metabolic control, reduced liver size, and no progression of multiple hepatic adenomas. On confirmation of each pregnancy, early in the first trimester nightly feeding was changed from cornstarch ingestion to Polycose by nasogastric intubation, with good metabolic control. During the last trimester of each pregnancy metabolic control showed further improvement, with lowering of lactate, urate, and triglyceride levels. During the first pregnancy unexpected fetal death occurred at 33 weeks. During the last two pregnancies, the patient was admitted at 33 and 34 weeks, respectively, for closer supervision of metabolic status and fetal monitoring. She underwent a cesarean section at 35 weeks 4 days of gestation and was delivered of a girl. She underwent a repeat cesarean section at 35 weeks 2 days for the subsequent gestation and was delivered of a boy. Both infants are healthy and appear to be unaffected by von Gierke's disease. Hepatic adenomas did not enlarge during the pregnancies. Meticulous management resulted in normal pregnancy outcomes in two consecutive gestations. Rapid fetal growth late in the third trimester may require particularly careful supervision to maintain euglycemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8203427

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

1.  Pregnancy in glycogen storage disease type Ib: gestational care and report of first successful deliveries.

Authors:  Aditi I Dagli; Philip J Lee; Catherine E Correia; Christina Rodriguez; Kaustav Bhattacharya; Linda Steinkrauss; Charles A Stanley; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2010-04-13       Impact factor: 4.982

Review 2.  Inborn errors of metabolism and pregnancy.

Authors:  J H Walter
Journal:  J Inherit Metab Dis       Date:  2000-05       Impact factor: 4.982

Review 3.  Glycogen storage diseases: new perspectives.

Authors:  Hasan Ozen
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

4.  Glycogen Storage Disease type 1a - a secondary cause for hyperlipidemia: report of five cases.

Authors:  Patrícia Margarida Serra Carvalho; Nuno José Marques Mendes Silva; Patrícia Glória Dinis Dias; João Filipe Cordeiro Porto; Lèlita Conceição Santos; José Manuel Nascimento Costa
Journal:  J Diabetes Metab Disord       Date:  2013-06-06

5.  Fertility and pregnancy in women affected by glycogen storage disease type I, results of a multicenter Italian study.

Authors:  Annalisa Sechi; Laura Deroma; Annunziata Lapolla; Sabrina Paci; Daniela Melis; Alberto Burlina; Francesca Carubbi; Miriam Rigoldi; Maja Di Rocco
Journal:  J Inherit Metab Dis       Date:  2012-05-05       Impact factor: 4.982

6.  Pregnancies in glycogen storage disease type Ia.

Authors:  Daniëlle H J Martens; Jan Peter Rake; Martin Schwarz; Kurt Ullrich; David A Weinstein; Martin Merkel; Pieter J J Sauer; G Peter A Smit
Journal:  Am J Obstet Gynecol       Date:  2008-02-01       Impact factor: 8.661

Review 7.  Impact of pregnancy on inborn errors of metabolism.

Authors:  Gisela Wilcox
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

8.  Double filtration plasmapheresis for pregnancy with hyperlipidemia in glycogen storage disease type Ia: A case report.

Authors:  Jie Wang; Yi Zhao; Pan Chang; Bin Liu; Rong Yao
Journal:  World J Clin Cases       Date:  2022-10-06       Impact factor: 1.534

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.